rational drug design


Also found in: Acronyms.

rational drug design

The study of the shape of molecules in order to determine how they will bind receptors on cells or combine with other molecules. Drug design that is based on molecular shape or architecture is an alternative to blindly testing hundreds of molecules to see if one or more of them will bind cellular or molecular targets.
Mentioned in ?
References in periodicals archive ?
Based in Dallas, Texas, the Company's lead programs involve paclitaxel (active ingredient in Taxol(R)) production using fermentation and genetic engineering in agreements with Bristol-Myers Squibb, the treatment of polycystic kidney disease using paclitaxel, breast cancer treatment by peptide inhibition of estrogen receptors and Quantum Core Technology(TM), a proprietary rational drug design.
He will assist Cytoclonal in the synthesis of drugs from its rational drug design program through consulting and contract work.
Nasdaq: PCOP), to optimize Cytoclonal's rational drug design efforts for improving diagnostics and therapeutics for cancer and infectious diseases such as HIV.
Cambridge, MA) using structure-based rational drug design.
The Company is a leader in the use of structure- based rational drug design, an approach to drug discovery that integrates biophysics, biology and medicinal chemistry.
They will then work with Immunex scientists on laboratory activities involving molecular biology, rational drug design and immunobiology.
The experience and expertise they bring to TBC will be important assets in the successful integration of IPI's rational drug design technology with TBC's therapeutics program for treating cardiovascular and inflammatory diseases.
In February, DOR announced that it had initiated a rational drug design program to identify oral, small molecule drugs to counter the deadly effects of botulinum toxin exposure through a collaboration with Blue Dolphin, LLC, a firm specializing in rational drug design.
IPI), a rational drug design company focused on developing small molecule therapeutics.
In 2003 the Company introduced the TOPAZ(R) system, which speeds the discovery of protein structure, an essential step in rational drug design.
The patent, titled "A Method of Rational Drug Design of Compounds that Mimic Conformational Features of Selected Peptides," covers a supercomputer-based method that is proprietary to IPI.

Full browser ?